SKYE insider transaction filings
Skye Bioscience, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen SKYE transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 22 legs across 4 filings by 9 insiders — 819,464 shares, $410,093 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
- Largest priced transaction: sale of 253,080 shares @ $0.38 ($96,170) by Schwab Andrew J., filed 2026-08-20.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| 5AM Partners VII, LLC — 10% owner & 5AM Ventures VII, L.P. — 10% owner & 5AM Partners II, LLC — 10% owner & 5AM Ventures II LP — 10% owner & 5AM CO-INVESTORS II LP — 10% owner & DIEKMAN JOHN D — 10% owner & PARMAR KUSH — 10% owner & ROCKLAGE SCOTT M — 10% owner | 2 | — | 11 legs · 409,732 sh · $205,047 | — |
| Schwab Andrew J. — Director, 10% owner | 2 | — | 11 legs · 409,732 sh · $205,047 | — |
| DHILLON PUNIT — Chief Executive Officer, Director | 1 | — | — | 1 |
Recent Form 4 filings — Skye Bioscience, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Schwab Andrew J. — Director, 10% owner | Sale (S): 32,607 @ $1.91 · Sale (S): 1,285 @ $1.91 | EDGAR |
| 2026-09-18 | 4 | 5AM Partners VII, LLC — 10% owner 5AM Ventures VII, L.P. — 10% owner 5AM Partners II, LLC — 10% owner 5AM Ventures II LP — 10% owner 5AM CO-INVESTORS II LP — 10% owner DIEKMAN JOHN D — 10% owner PARMAR KUSH — 10% owner ROCKLAGE SCOTT M — 10% owner | Sale (S): 32,607 @ $1.91 · Sale (S): 1,285 @ $1.91 | EDGAR |
| 2026-08-20 | 4 | Schwab Andrew J. — Director, 10% owner | Sale (S): 45,090 @ $0.38 · Sale (S): 1,830 @ $0.38 · Sale (S): 253,080 @ $0.38 · Sale (S): 10,255 @ $0.35 · Sale (S): 409 @ $0.35 · Sale (S): 57,476 @ $0.35 · +3 more | EDGAR |
| 2026-08-20 | 4 | 5AM Partners VII, LLC — 10% owner 5AM Ventures VII, L.P. — 10% owner 5AM Partners II, LLC — 10% owner 5AM Ventures II LP — 10% owner 5AM CO-INVESTORS II LP — 10% owner DIEKMAN JOHN D — 10% owner PARMAR KUSH — 10% owner ROCKLAGE SCOTT M — 10% owner | Sale (S): 45,090 @ $0.38 · Sale (S): 1,830 @ $0.38 · Sale (S): 253,080 @ $0.38 · Sale (S): 10,255 @ $0.35 · Sale (S): 409 @ $0.35 · Sale (S): 57,476 @ $0.35 · +3 more | EDGAR |
| 2026-08-07 | 4 | DHILLON PUNIT — Chief Executive Officer, Director | Grant/award (A): 1,090,000 @ $0 | EDGAR |
| 2026-04-02 | 4 | Smith Karen L. — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Twitty Christopher — Chief Scientific Officer | Grant/award (A): 17,004 (derivative) · Disposition to issuer (D): 17,004 (derivative) · Grant/award (A): 75,000 (derivative) · Disposition to issuer (D): 75,000 (derivative) · Grant/award (A): 7,100 (derivative) · Disposition to issuer (D): 7,100 (derivative) · +6 more | EDGAR |
| 2026-04-02 | 4 | Jenkins Annalisa — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Charych Deborah H. — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Grayson Paul A. — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Schwab Andrew J. — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Diep Tuan Tu — Chief Operating Officer | Grant/award (A): 150,000 (derivative) · Disposition to issuer (D): 150,000 (derivative) · Grant/award (A): 9,194 (derivative) · Disposition to issuer (D): 9,194 (derivative) · Grant/award (A): 22,021 (derivative) · Disposition to issuer (D): 22,021 (derivative) · +8 more | EDGAR |
| 2026-04-02 | 4 | DHILLON PUNIT — Chief Executive Officer, Director | Grant/award (A): 250,000 (derivative) · Disposition to issuer (D): 250,000 (derivative) · Grant/award (A): 36,000 (derivative) · Disposition to issuer (D): 36,000 (derivative) · Grant/award (A): 12,360 (derivative) · Disposition to issuer (D): 12,360 (derivative) · +8 more | EDGAR |
| 2026-02-09 | 4 | Schwab Andrew J. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Grayson Paul A. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Smith Karen L. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | ARSENAULT KAITLYN — Chief Financial Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Twitty Christopher — Chief Scientific Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Charych Deborah H. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Jenkins Annalisa — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Diep Tuan Tu — Chief Development Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Arora Puneet S. — Chief Medical Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | DHILLON PUNIT — Chief Executive Officer, Director | Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
| 2025-08-22 | 4 | Schwab Andrew J. — Director, 10% owner | Sale (S): 58,642 @ $3.57 · Sale (S): 2,314 @ $3.57 · Sale (S): 163,979 @ $3.42 · Sale (S): 6,470 @ $3.42 | EDGAR |
| 2025-08-22 | 4 | 5AM Partners VII, LLC — 10% owner 5AM Ventures VII, L.P. — 10% owner 5AM Partners II, LLC — 10% owner 5AM Ventures II LP — 10% owner 5AM CO-INVESTORS II LP — 10% owner DIEKMAN JOHN D — 10% owner PARMAR KUSH — 10% owner ROCKLAGE SCOTT M — 10% owner | Sale (S): 58,642 @ $3.57 · Sale (S): 2,314 @ $3.57 · Sale (S): 163,979 @ $3.42 · Sale (S): 6,470 @ $3.42 | EDGAR |
| 2025-02-28 | 4/A | ARSENAULT KAITLYN — Chief Financial Officer | Sale (S): 190 @ $5.55 · Sale (S): 43,026 @ $4.99 | EDGAR |
| 2025-02-26 | 4 | Schwab Andrew J. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | ARSENAULT KAITLYN — Chief Financial Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Jenkins Annalisa — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Grayson Paul A. — Director | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Smith Karen L. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Charych Deborah H. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Diep Tuan Tu — Chief Development Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Arora Puneet S. — Chief Medical Officer | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | DHILLON PUNIT — Chief Executive Officer, Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-11-20 | 4 | Diep Tuan Tu — Chief Development Officer | Sale (S): 85 @ $5.55 · Sale (S): 19,489 @ $4.99 | EDGAR |
| 2024-11-19 | 4 | Grayson Paul A. — Director | Sale (S): 307 @ $5.55 · Sale (S): 86,244 @ $4.99 | EDGAR |
| 2024-11-19 | 4 | ARSENAULT KAITLYN — Chief Financial Officer | Sale (S): 190 @ $5.55 · Sale (S): 43,206 @ $4.99 | EDGAR |
| 2024-11-19 | 4 | DHILLON PUNIT — Chief Executive Officer, Director | Sale (S): 364 @ $5.55 · Sale (S): 82,546 @ $4.99 | EDGAR |
| 2024-10-30 | 4 | Grayson Paul A. — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | Diep Tuan Tu — Chief Development Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | ARSENAULT KAITLYN — Chief Financial Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | Schwab Andrew J. — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | Smith Karen L. — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | Charych Deborah H. — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | Jenkins Annalisa — Director | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | DHILLON PUNIT — Chief Executive Officer, Director | Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
| 2024-09-13 | 4 | Schwab Andrew J. — Director, 10% owner | Sale (S): 214,556 @ $6.60 · Sale (S): 36,504 @ $6.60 · Sale (S): 1,440 @ $6.60 · Sale (S): 11,758 @ $6.06 · Sale (S): 2,000 @ $6.06 · Sale (S): 79 @ $6.06 | EDGAR |
| 2024-09-13 | 4 | 5AM Partners VII, LLC — 10% owner 5AM Ventures VII, L.P. — 10% owner 5AM Partners II, LLC — 10% owner 5AM Ventures II LP — 10% owner 5AM CO-INVESTORS II LP — 10% owner DIEKMAN JOHN D — 10% owner PARMAR KUSH — 10% owner ROCKLAGE SCOTT M — 10% owner | Sale (S): 214,556 @ $6.60 · Sale (S): 36,504 @ $6.60 · Sale (S): 1,440 @ $6.60 · Sale (S): 11,758 @ $6.06 · Sale (S): 2,000 @ $6.06 · Sale (S): 79 @ $6.06 | EDGAR |
| 2024-09-04 | 4 | Arora Puneet S. — Chief Medical Officer | Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Skye Bioscience, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-11 | 8-K | 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2026-08-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-20 | 8-K/A | 3.03 — Material Modification to Rights of Security Holders | EDGAR |
| 2026-08-19 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-29 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-04-06 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-04-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SKYE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →